Wedbush Issues Pessimistic Outlook for Nuvation Bio Earnings

Nuvation Bio Inc. (NYSE:NUVB) – Equities research analysts at Wedbush lowered their Q3 2025 EPS estimates for shares of Nuvation Bio in a report issued on Monday, March 3rd. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.17) for the quarter, down from their prior forecast of ($0.16). Wedbush currently has a “Outperform” rating and a $5.00 target price on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Nuvation Bio’s Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.62) EPS, FY2026 earnings at ($0.73) EPS and FY2027 earnings at ($0.48) EPS.

NUVB has been the topic of several other reports. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 price target (up from $6.00) on shares of Nuvation Bio in a research report on Tuesday, January 7th. HC Wainwright raised their price target on shares of Nuvation Bio from $10.00 to $11.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Nuvation Bio presently has a consensus rating of “Buy” and a consensus target price of $8.20.

Nuvation Bio Price Performance

NYSE NUVB opened at $2.03 on Thursday. The company has a market cap of $681.55 million, a P/E ratio of -0.93 and a beta of 1.47. Nuvation Bio has a 12 month low of $1.67 and a 12 month high of $4.16. The company has a 50-day moving average of $2.42 and a 200-day moving average of $2.59.

Hedge Funds Weigh In On Nuvation Bio

A number of institutional investors have recently made changes to their positions in the business. Forum Financial Management LP bought a new stake in shares of Nuvation Bio in the fourth quarter worth $29,000. Cerity Partners LLC bought a new stake in shares of Nuvation Bio in the 4th quarter worth about $31,000. Russell Investments Group Ltd. lifted its position in shares of Nuvation Bio by 15,183.7% during the fourth quarter. Russell Investments Group Ltd. now owns 15,895 shares of the company’s stock worth $42,000 after purchasing an additional 15,791 shares during the last quarter. Abacus Planning Group Inc. acquired a new position in Nuvation Bio in the fourth quarter worth about $44,000. Finally, Cibc World Markets Corp bought a new stake in Nuvation Bio in the fourth quarter valued at about $45,000. 61.67% of the stock is owned by institutional investors and hedge funds.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.